E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The aim of this study is to reduce the kidney uptake during 111In-DTPA- exendin4 imaging, a promising and valuable tool for beta-cell mass imaging and quantification, which can be applied in patients with e.g. diabetes. |
|
E.1.1.1 | Medical condition in easily understood language |
The aim of this study is to improve the image quality obtained with a tracer specifically targeting insulin producing cells, which is of great interest for patients with e.g. diabetes. |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | HLGT |
E.1.2 | Classification code | 10018424 |
E.1.2 | Term | Glucose metabolism disorders (incl diabetes mellitus) |
E.1.2 | System Organ Class | 10014698 - Endocrine disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10012602 |
E.1.2 | Term | Diabetes mellitus (incl subtypes) |
E.1.2 | System Organ Class | 10014698 - Endocrine disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10012601 |
E.1.2 | Term | Diabetes mellitus |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10067584 |
E.1.2 | Term | Type 1 diabetes mellitus |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to determine whether the administration of Gelofusine will reduce the kidney uptake of 111Inlabeled exendin in humans by enhancing the excretion of 111In-labeled exendin. These highly relevant data can potentially improve the interpretation of clinical quantitative SPECT and can have important implications for imaging of pancreatic beta cell mass in diabetes patients as well as therapeutic decision making for patients with insulinomas or congenital hyperinsulinism. |
|
E.2.2 | Secondary objectives of the trial |
Determine whether the administration of Gelofusine affects pancreatic uptake of 111In-labeled exendin based on quantitative analysis of SPECT images. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion criteria • >= 18 years • <= 60 years • Normal renal function (creatinine clearance > 90mL/min according to the formula of Cockroft and Gault) • Normal glucose regulation (HbA1c 53 /mol (7%)) • BMI 17>30 |
|
E.4 | Principal exclusion criteria |
• Use of any medication affecting renal function • Known hypersensitivity to one of the substances used • Hypertension • Oedema • Hypervolaemia • Heart failure • Pregnancy or the wish to become pregnant within 3 months after participation of the study. • Lactation • History of anaphylaxis • Liver disease defined as aspartate aminotransferase or alanine aminotransferase level more than 3 times the upper limit of normal range (45U/L) • History of pancreatitis
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The main study parameter is the renal uptake of 111In-DTPA-[K40]-Exendin 4 based on quantitative SPECT imaging with and without co-infusion of Gelofusine. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
In total patients will undergo two exendin injections : one with gelofusine and one with saline as a control (the order will be randomly assigned). There will be at least three weeks between the exendin injections to prevent influence of the previous injection. The first two patients will undergo two SPECT-scans after exendin injections (four scans in total): 4h and 24h post injection. Based on these data one time-point for analysis is selected and the other patients will receive two scans in total. |
|
E.5.2 | Secondary end point(s) |
The secondary study parameter is the pancreatic uptake of 111In-DTPA-[K40]-Exendin 4 based on quantitative SPECT imaging with and without co-infusion of Gelofusine. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
In total patients will undergo two exendin injections : one with gelofusine and one with saline as a control (the order will be randomly assigned). There will be at least three weeks between the exendin injections to prevent influence of the previous injection. The first two patients will undergo two SPECT-scans after exendin injections (four scans in total): 4h and 24h post injection. Based on these data one time-point for analysis is selected and the other patients will receive two scans in total. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
The scope of this trial is to see whether gelofusine can reduce kidney uptake of 111In0DTPA-[k40]-exendin4 and to see whether this affects the pancreatic uptake. |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |